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E-mail: tero.jarvinen@tuni.fiSystemic skin-selective therapeutics would be a major advance-
ment in the treatment of diseases affecting the entire skin, such
as recessive dystrophic epidermolysis bullosa (RDEB), which is
caused by mutations in the COL7A1 gene and manifests in
transforming growth factor-b (TGF-b)-driven fibrosis and
malignant transformation. Homing peptides containing a
C-terminal R/KXXR/K motif (C-end rule [CendR] sequence)
activate an extravasation and tissue penetration pathway for tu-
mor-specific drug delivery. We have previously described a
homing peptide CRKDKC (CRK) that contains a cryptic
CendR motif and homes to angiogenic blood vessels in wounds
and tumors, but it cannot penetrate cells or tissues. In this
study, we demonstrate that removal of the cysteine from CRK
to expose the CendR sequence confers the peptide novel ability
to home to normal skin. Fusion of the truncated CRK (tCRK)
peptide to the C terminus of an extracellular matrix protein de-
corin (DCN), a natural TGF-b inhibitor, resulted in a skin-
homing therapeutic molecule (DCN-tCRK). Systemic DCN-
tCRK administration in RDEB mice led to inhibition of
TGF-b signaling in the skin and significant improvement in
the survival of RDEB mice. These results suggest that DCN-
tCRK has the potential to be utilized as a novel therapeutic
compound for the treatment of dermatological diseases such
as RDEB.
INTRODUCTION
A general limitation in systemic drug delivery is that only a small frac-
tion of drug reaches its desired location and systemic side effects are
encountered in other organs. Thus, a critical goal of modern drug
development is to generate drugs to be target organ-specific, with
minimal adverse effects in the other parts of the body. This goal could
be achieved by developing drugs that recognize a specific epitope ex-Molec
This is an open access article under thpressed in the affected organ. Alternatively, drugs can be converted to
be target-specific by conjugation with an affinity ligand such as a
homing peptide.1–3 In vivo screening of phage peptide libraries has
identified organ- or disease-specific molecular signatures in the
vascular tissues, enabling a postal code system (vascular zip codes)
for target-specific delivery of systemically administered therapeu-
tics.2–4 The most efficient vascular homing peptides for tumor-spe-
cific cell and tissue penetration contain a consensus motif R/KXXR/
K, with an arginine (or rarely lysine) residue at the C terminus,
thus called a C-end rule (CendR) sequence.5–8 The CendR sequence
binds to neuropilin-1 (NRP-1), activating an extravasation and tissue
penetration pathway that delivers the peptide along with its payload
into the parenchyma of the tumor tissue.3,5,8 As NRP-1 is expressed
by the endothelial cells in all tissues,3 peptides containing cryptic
CendR owe their target selectivity to a combination of binding to
primary receptor with a tumor-specific expression pattern, and to a
proteolytic activation to expose the CendR sequence in the target
organ.5–8
Being the largest organ of the human body, skin presents unique chal-
lenges for efficient drug delivery. The primary challenge related to
local, i.e., transdermal, drug delivery is the poor penetration of mac-
romolecules into the skin. Diffusion through intercellular lipidsular Therapy Vol. 28 No 8 August 2020 ª 2020 The Author(s). 1833
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Molecular Therapyprovides a transdermal delivery option, but it is limited only for the
delivery of small lipophilic molecules. Therefore, systemically admin-
istered, yet skin-specific therapeutics would be a substantial therapeu-
tic advance for the treatment of skin diseases, particularly those that
affect the entire skin, such as recessive dystrophic epidermolysis bul-
losa (RDEB). RDEB is caused by mutations in the COL7A1 gene that
encodes type VII collagen (C7).9–12 Clinical manifestations include
skin erosions and blistering, mutilating scarring, pseudosyndactyly,
and a high risk of developing aggressive and rapidly metastasizing
cutaneous squamous cell carcinomas (cSCCs).10,11,13–16 Although
novel gene-, cell-, and protein-based therapies have demonstrated
promising results in delivering C7 to the skin, challenges remain
and there is still no cure for RDEB.13–16 TGF-b signaling has been
demonstrated to play an essential role in the development of fibrosis
and in the progression to malignancy in RDEB.17–19 Our previous
study demonstrated that TGF-b signaling is activated as early as a
week after birth in col7a1/ mice.20 Thus, an early intervention on
the activation of TGF-b signaling may be beneficial in reducing dis-
ease burden in RDEB. TGF-b signaling has also been suggested to
be a phenotypic modulator in monozygotic twins with identical
COL7A1 mutations.18 Moreover, the expression level of a proteogly-
can decorin (DCN), a natural TGF-b inhibitor, was significantly
higher in the less affected twin. DCN is a structural constituent of
extracellular matrix (ECM), and Dcn/ mice exhibit irregular
collagen fibril formation and significantly reduced tensile strength
in skin.21 Furthermore, DCN has anti-fibrotic and anti-tumor func-
tions by regulating activities of multiple growth factors, among
them inhibitory action on TGF-b.22,23 We recently also demonstrated
an upregulation of DCN expression as one of the mechanisms of ac-
tion for the effects of cord blood-derived unrestricted somatic stem
cells (USSCs) in col7a1/ mice.20 Supporting the role of DCN as a
potential therapeutic disease-modifying molecule for RDEB, Cianfar-
ani et al.24 recently reported that systemic administration of lentivirus
driving the expression of human DCN (hDCN) attenuated TGF-
b-induced fibrosis in a C7-hypomorphic RDEBmouse model that ex-
presses a residual level of C7 (C7-hypomorphic mice).
Our past in vivo phage display screens identified a panel of peptides
that home to angiogenic blood vessels in skin wounds.25 Two of the
most promising peptides, cyclic peptides dubbed CAR
(CARSKNKDC) and CRK (CRKDKC), have been utilized to deliver
different therapeutic molecules in a target-selective fashion.1 Interest-
ingly, whereas CRK peptide contains a cryptic CendR sequence,
RKDK, it is the only peptide among the vascular-homing CendR pep-
tides that is not capable of penetrating cells and tissues.25,26 In this
study, we demonstrate that C-terminal exposure of the cryptic
CendR-sequence of CRK, i.e., truncated CRK (tCRK; CRKDK), con-
fers the peptide the ability to home to and penetrate normal skin while
retaining its ability to home to skin wounds. This novel targeting
specificity can be used for therapeutic benefit; that is, recombinant
DCN-tCRK fusion protein had a superior therapeutic effect
compared to native DCN in a col7a1/ RDEB mouse model that
completely lacks expression of C7.1834 Molecular Therapy Vol. 28 No 8 August 2020RESULTS
tCRK Peptide Homes to Skin Wounds and Normal Skin
We previously characterized the homing of CAR and CRK peptides to
skin wounds at different phases of wound healing.25 As CRK contains
a cryptic CendR motif, but is not capable of penetrating cells and tis-
sues,25,26 we set out to investigate whether truncation of CRK by
removing the last cysteine residue to expose the CendR motif at the
C terminus would change its homing and/or tissue-penetration
properties.
We first determined the homing of tCRK to wounded skin at day 7 at
the peak of angiogenesis. Similar to our previous report on CAR and
CRK,25 the phage carrying tCRK peptide homed to the wound 112 ±
71.2-fold higher than the nonrecombinant control phage (p < 0.001,
n = 8) (Figure 1A). The wound homing of tCRK was not statistically
different from phage displaying CAR peptide (101 ± 89.3-fold higher
than negative control, n = 5), but it was significantly better than the
CRK phage (15.5 ± 8.19-fold, p < 0.05, n = 8) (Figure 1A). Our pre-
vious studies also showed that CAR, but not CRK, homes to early
angiogenic blood vessel sprouts in day 5 wounds.25 In this study,
we observed that tCRK also homes to the day 5 wound at a signifi-
cantly higher level than the nonrecombinant phage (6.14 ± 1.41-
fold, p < 0.05, n = 9) (Figure S1).
As wound healing progresses, the granulation tissue rich in angio-
genic blood vessels gradually converts to scar tissue with a limited
number of blood vessels. The homing of CRK and CAR were dimin-
ished to 13.6 ± 2.66-fold (p < 0.001, n = 7) and 20.7 ± 4.72-fold (p <
0.001, n = 7) when compared to the control phage at the excisional
wound on day 14 (Figure 1B). In contrast, there was an ~35-fold
enrichment of tCRK peptide at this time point (34.3 ± 9.78-fold,
p < 0.001, n = 7). These results show that tCRK homes to skin wounds
at different phases of wound healing and is able to home to wounds
that have matured to scar tissue.
There was no overrepresentation of the phages displaying tCRK,
CAR, or CRK peptides at other organs, including lung, heart, spleen,
kidney, and liver (Figure 1C). Surprisingly, in addition to homing to
the wound, tCRK was also detected in normal skin, 3 cm or farther
from the edge of the wound (Figure 1C), and the enrichment
(11.2 ± 9.16-fold) was remarkably higher than any other studied
phage clones. To exclude possible influence of a nearby wound on
the tCRK homing to normal skin, we investigated the skin homing
property of tCRK in mice without wounds. Indeed, about 20-fold
(20.5 ± 5.67-fold, p < 0.001, n = 7) enrichment of tCRK compared
to the control phage was seen in the normal skin (Figure 1D). This
was significantly higher (p < 0.05) than that of CRK (5.04 ± 2.88-fold).
To confirm that tCRK peptide indeed homes to both normal skin and
skin wounds, we generated nanoparticles, iron oxide nanoworms
(IONWs), and coupled them with/without tCRK-homing peptides.
IONWs were synthesized and characterized as described previously.27
Fluorescent tCRK, a scrambled CendR peptide (negative control
Figure 1. Homing of tCRK Phage
The amounts are represented as fold over control phage. (A)
Phage homing in 7-day-old wound. n = 8 for tCRK and
CRK, n = 5 for CAR, and n = 7 for control phage. (B) Phage
homing in 14-day-old wound. n = 7 for tCRK, CRK, and
CAR, and n = 5 for control phage. (C) Phage homing in
control organs. n = 11 for tCRK and control phage, n = 10
for CRK, and n = 5 for CAR. (D) Phage homing in un-
wounded skin. n = 7 for all phages. Error bars represent
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, Kruskal-Wallis test
with Bonferroni post hoc test.
www.moleculartherapy.orgdubbed PRP), or FAM label alone was coated on the IONWs through
a thioether bond between the cysteine thiol from the peptide and the
maleimide on the IONWs.28 The IONWs were injected into mice
with either excision wounds with splints or without splints. Only
tCRK-coated IONWs, but not control peptide or FAM-coated
IONWs, were detected throughout the blood vessels of the normal
dermis (taken farther than 5 cm from the wounds) (Figure 2). In
both excision wound models, strong accumulation of tCRK-coated
IONWs was detected in hypervascular regions of the wounds,
whereas these hypervascular regions were almost devoid of control
peptide or FAM-coated IONWs (Figure S2). These results further
confirmed that exposure of cryptic CendR sequence facilitates
tCRK to be not only a potent wound-homing peptide but also a pep-
tide homing to normal skin.
Generation of Multi-Functional, Recombinant DCN-tCRK Fusion
Protein
We next engineered DCN-tCRK fusion protein by placing tCRK pep-
tide at the C terminus ofDCN (Figure 3A). BothDCN-tCRK andnative
DCN were expressed in mammalian cells and purified using chroma-
tography (Figure S3A). Both recombinant proteins migrated as sharp
bands at about 55 kDa with a smear above the band in SDS gel electro-
phoresis and detected as DCN by western blot analysis (Figure S3B).
The sharp band corresponds to the core protein, and the smear is caused
by heterogeneity in the glycosaminoglycan sulfate chain (mostly chon-Modroitin) attached to theDCN core.Mass spectrom-
etry validated the identity ofDCNand theC-termi-
nal tCRK sequence (Table S1). The hydrodynamic
size indicates that DCN-tCRK exists as homoge-
neous and non-aggregated macromolecules with
a diameter consistent with the reported dimer of
DCN29 (Figure S3C). Differential scanning calo-
rimetry produced a sharp peak with amelting tem-
perature (Tm)of 49C, suggesting that tCRK-DCN
will maintain a stable tertiary structure at a physio-
logical condition (Figure S3D).
DCN-tCRK Interacts with NRP-1 In Vitro
We next investigated whether the tCRK peptide
fused to DCN retains its ability to interact with
NRP-1. We immobilized DCN-tCRK on ELISAplates and tested its binding to wild-type (WT) or mutant NRP-1,
where the CendR-binding pocket was disabled by a triple mutation.6
DCN-tCRK effectively binds to WT NRP-1 at a significantly higher
level than the control bovine serum albumin (BSA) (p < 0.01),
whereas it showed no significant binding to the mutant NRP-1 (p >
0.05) (Figure 3B). Furthermore, parallel studies with a synthetic
RPARPAR peptide, a prototypic CendR peptide, and RPARPARA,
a control peptide with a C-terminally capped CendR sequence and
unable to interact with NRP-1, were used to fortify that the binding
is dependent on CendR sequence (Figure 3B). We further determined
whether DCN-tCRK binds to the cells that express NRP-1, i.e., human
PC3 prostate carcinoma cells. M21 melanoma cells that do not ex-
press NRP-1 were also included in the assay. Supporting the NRP-
1-dependent cell binding and penetration properties, internalization
of DCN-tCRK was observed only in the NRP-1-positive PC3 cells,
but not in the NRP-1-negative M21 cells (Figure 3C).
DCN-tCRK and DCN Exhibited Similar Pharmacokinetics In Vivo
To determine whether the addition of tCRK peptide had any effect on
the circulation half-life of DCN, DCN-tCRK and DCN were injected
intravenously in parallel in healthy BALB/c mice, and their amount in
peripheral blood at different time points within 24 h of administra-
tion was quantitated by ELISA. The half-life of DCN-tCRK in blood
was 30 min and was not significantly different from that of DCN (Fig-
ure S4). The pharmacokinetic studies suggest that modification oflecular Therapy Vol. 28 No 8 August 2020 1835
Figure 2. Homing of tCRK-Coated Nanoparticles to
Normal Skin
Representative images of immunohistochemical staining of
skin samples from BALB/c mice with anti-FITC (fluorescein
isothiocyanate) (red) to detect the intravenously (i.v.) in-
jected FAM-labeled IONWs coated with tCRK (12mg/kg), a
control peptide (PRP) (16 mg/kg), or no peptide (13 mg/kg).
The localization of blood vessels is depicted by anti-CD31
(green), and nuclei are stained with DAPI (blue). Scale bar,
100 mm. Representative images are from three indepen-
dent experiments.
Molecular TherapyDCN with small vascular-homing peptide does not influence the
pharmacokinetics of DCN.
DCN-tCRK Administration Improves the Survival of col7a1–/–
Mice
We next evaluated the therapeutic function and skin-homing proper-
ties of DCN and DCN-tCRK in col7a1/ mice, an animal model of
RDEB. Thesemice are generated by breeding of the heterozygous litter-
mates, and col7a1/mice can be identified at birth based on themani-
festation of hemorrhagic blistering in the skin.30 The newborn
col7a1/ mice were randomly divided to receive DCN, DCN-tCRK,
or PBS (negative control) via intrahepatic administration. Repeated
intraperitoneal (i.p.) administration was performed to the surviving
mice within each group every other day after the first dose until day
14. In this study, themedian lifespan of col7a1/mice was 2 days after
PBS injection and it was significantly prolonged to 7 days after admin-
istration of DCN (p < 0.0001) (Figure 4A). However, the survival of
col7a1/ mice after DCN administration was not statistically signifi-
cant as compared to a historical administration of dextran/human
serum albumin (D/HSA), which was used as the vehicle for stem cell
administration and sporadically increased the survival of some
col7a1/ recipient mice likely by adjusting fluid balance (Figure S5).31
Moreover, DCN injections did not extend the survival of the recipients
beyond 2 weeks of age. Importantly, the median lifespan of the mice
after DCN-tCRK treatment was further extended to 11 days, which
was significantly better than that after either PBS (p < 0.0001) or histor-1836 Molecular Therapy Vol. 28 No 8 August 2020ical D/HSA administration (p < 0.001) (Figures
4A and S5). In addition, 85% of DCN-tCRK-
treated mice reached 7 days of survival, and 20%
of these mice survived past 3 weeks of age and
were subsequently sacrificed for skin analyses.
DCN-tCRK Homes in Skin of col7a1–/– Mice
We next utilized an ELISA assay to quantitate
hDCN and DCN-tCRK in the skin of recipient
RDEB mice at 1, 2, and 3 weeks (n = 3 for all
time points) (Figure 4B). There was no statisti-
cally significant difference between DCN-tCRK-
and DCN-treated skin at the 1-week time point.
However, the level of DCN-tCRK at the 2-week
time point was significantly higher than that ofDCN (3.6-fold, p < 0.05) (Figure 4B). In addition, as the last i.p.
administration of DCN-tCRK was conducted on day 14, identifica-
tion of DCN-tCRK in the 3-week skin (19.47 ± 12.80 pg/mL) is highly
suggestive of its stability in vivo for at least 7 days.
We also performed immunohistochemical staining based on the
expression of histidine tag to analyze the anatomical distribution of
DCN-tCRK or DCN in the RDEB skin. DCN-tCRK was detected in
the dermis of both the paw and dorsal skin of the RDEB mice at 1,
2, and 3 weeks (Figure 4C). Moreover, staining of the gastrointestinal
(GI) tract of the recipient RDEB mice did not reveal reactivity with
anti-his antibody (data not shown), suggestive of a skin-specific tar-
geting of DCN-tCRK. In contrast, although ELISA demonstrated
the presence of DCN in the skin lysate, the anti-his immunostaining
on DCN-treated RDEB skin, represented by the 1-week time point,
only appeared to be non-specific (diffuse) (Figure 4C). Further sup-
porting our hypothesis that the homing of DCN-tCRK is afforded
by NRP-1-dependent cell and tissue penetration, the anti-his and
anti-NRP-1 double staining demonstrated that the signal from
DCN-tCRK was within or in a close proximity to the cells that were
positive for NRP-1 in RDEB skin (Figure 4D).
DCN-tCRKTherapySuppresses the FibroticResponses inRDEB
Mice
Our recent studies demonstrated a significant elevation of TGF-b
signaling in col7a1/ mice beginning in the interdigital folds of
Figure 3. Recombinant DCN-tCRK Protein and Its
Binding to Neuropilin-1
(A) A schematic representation of the structure of DCN-
tCRK. Signal peptide and propeptide of the native DCN
were replaced with a 6 His-tag (I) for purification. The His-
tag is followed by the amino terminus (II), core protein (III),
and carboxyl terminus (IV) of mature DCN proteoglycan.
tCRK peptide (V) was cloned on the carboxyl end of the
protein. (B) In vitro binding of DCN-tCRK to neuropilin-1
(NRP-1) in vitro. DCN-tCRK (left panel) and peptide controls
(right panel, positive peptide [RPARPAR] and negative
peptide [RPARPARA]) were immobilized in ELISA plate.
Bovine serum albumin (BSA) was included as a non-specific
protein control for DCN-tCRK and the peptides. WT and
mutant NRP-1 were labeled with FAM and added to the
immobilized plate. The binding of the NRP-1 was measured
based on fluorescence intensity. Error bars represent SEM.
Experiments were repeated with triplicate samples. **p <
0.01, ***p < 0.001, ****p < 0.0001, Student’s unpaired t test.
(C) Internalization of DCN-tCRK in the NRP-1-positive cells.
FAM-labeled DCN-tCRK was incubated with PC3 and M21
cells positive and negative for NRP-1 expression, respec-
tively. DCN-tCRK was detected by anti-FAM immuno-
staining (green). Nuclei were counterstained with DAPI
(blue). Representative images from three independently
studied experiments are shown. Scale bars, 20 mm.
www.moleculartherapy.orgthe paws as early as a week after birth.20 Therefore, in this study, we
chose the skin biopsies of this time point to compare the expression of
84 genes central to wound-healing responses and fibrosis formation
between the WT and vehicle (D/HSA)-, DCN-, or DCN-tCRK-
treated RDEB skin (n = 3 per group) (Table S2). Relative to the
WT, more than half of the genes showed a >1.5-fold increase in
expression in the vehicle-injected RDEB skin, as demonstrated in
the clustergram in Figure 5A. The relative fold changes (log2) of
gene expression and the p values (log10) are also presented as vol-
cano plots, and the significantly (p < 0.05) dysregulated genes are
marked in red in each plot (Figure 5B). The significantly upregulated
genes in the vehicle RDEB skin are involved in TGF-b signaling (i.e.,
Tgfb1, Tgfbr3, Ctgf), WNT signaling (Ctnnb1), mitogen-activatedMoprotein kinase (MAPK)1/MAPK3 signaling
(Mapk3), and epidermal growth factor receptor
(Egfr) signaling, ECM remodeling (Ctsg, Plaur),
cell adhesion (Itgb3, Itgb5), and inflammation
(Il4, Cxcl3, Tnfa). There were no significantly
downregulated genes in the vehicle RDEB skin
compared to the WT. In the DCN-treated
RDEB mouse skin, the overall gene expression
profile was similar to that in the vehicle RDEB
skin (Figure 5B). Even though the expression of
Tgfb1was no longer significantly abnormal, the
expression of Tgfbr3 and Ctgf was still signifi-
cantly upregulated in the DCN-treated RDEB
skin. Some genes, such as Il4, Cxcl3, and Tnfa,
were more significantly upregulated in theDCN-treated RDEB skin than in the vehicle control (Figure 5B;
Table S2).
Importantly, the expression profile of DCN-tCRK-treated RDEB skin
was markedly different from those of vehicle- and DCN-treated
RDEB skin and resembled that of WT skin (Figure 5A). Although
it showed individual variation in the expression of some genes,
none of the genes in the array was significantly dysregulated in
DCN-tCRK-treated RDEB skin when compared to the WT (Figure 5;
Table S2).
Supporting the development of TGF-b1-mediated fibrosis in un-
treated RDEB skin and its suppression by DCN-tCRK treatment,lecular Therapy Vol. 28 No 8 August 2020 1837
Figure 4. DCN-tCRK Improves Survival of col7a1–/– Mice and Homes to the Skin
(A) Kaplan-Meier survival analysis of the col7a1/mice that received DCN-tCRK (median lifespan, 11 days; n = 21; green line), DCN (median lifespan, 7 days; n = 17; purple
line), and PBS (median lifespan, 2 days; n = 24; red line) administration. (B) Quantitation on the levels of DCN and DCN-tCRK, determined using a human decorin ELISA kit, in
the skin of recipient col7a1/mice at 1 week, 2 weeks, and 3 weeks after intrahepatic administration (n = 3 per time point). There was no quantitation on the level of DCN at
the 3-week time point, as no mice survived until that time after DCN administration. Error bars represent SEM. *p < 0.05, **p < 0.01. (C) Immunohistochemical staining using
(legend continued on next page)
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www.moleculartherapy.orgstrong expression of CTGF/CCN2 was observed in vehicle-injected
RDEB skin, and the expression level was markedly diminished after
treatment with DCN-tCRK (Figure 6A). Moreover, the overall
collagen deposition increased with time in the vehicle-injected
RDEB skin, as demonstrated by picrosirius red staining, but was
significantly decreased in the DCN-tCRK-treated mouse skin (Fig-
ures 6B and 6C). Immunostaining demonstrated a substantial
increase in the expression of type I collagen (COL1) in the vehicle-
treated skin and an attenuated expression in the DCN-tCRK-treated
skin at the 2-week time point (Figures 6D and 6E). Similar results
were obtained with immunostaining of myofibroblasts, i.e., a-smooth
muscle actin (aSMA; Figures 6D and 6E). Moreover, most of the
aSMA+ cells in the WT as well as DCN-tCRK-treated RDEB skin
co-localized with blood vessels (CD31 staining), which indicates their
identity as blood vessel smooth muscle cells and pericytes, whereas
the aSMA+ cells in the vehicle-treated RDEB skin were outside of
the blood vessels, i.e., indicative of being myofibroblasts (Figure 6D).
To directly demonstrate the anti-fibrotic function of DCN-tCRK, we
compared the abilities of DCN and DCN-tCRK to suppress the
collagen gel contraction in vitro, using both normal and RDEB-
derived fibroblasts. At a low concentration (75 mM), at which DCN
had no significant effect on collagen contraction, DCN-tCRK sup-
pressed the collagen gel contraction in both normal (p < 0.05) and
RDEB-derived (p < 0.01) fibroblasts (Figure S6). These findings are
in line with our previous report that modification of DCN with a
vascular-homing peptide CAR makes the native DCN biologically
more active by enhancing its binding to target cells.23,32
DISCUSSION
We demonstrate that a C-terminal exposure of CendR sequence in a
wound-homing peptide renders a novel tissue-penetrating function
of the peptide in normal and wounded skin. Conjugation of tCRK
peptide to DCN facilitates skin-selective targeting of the therapeutic
fusion protein that exerts anti-fibrotic effects and improves survival
in a murine model of RDEB.
Currently, homing peptides containing a CendR motif are under
extensive investigation as a novel method to enhance the efficacy of
drug delivery in cancer treatment.2–4 Most CendR peptides, with
the exception of tLyP-1,33 contain cryptic CendR. Cryptic CendR
peptides home to tumor vasculature by binding to the receptor ex-
pressed selectively on tumor endothelium, where they are cleaved
by proteases and the cryptic CendR motif is exposed, after which it
can bind to NRP-1 for efficient cell and tissue penetration. None of
these peptides home to normal skin. The CendR motif in the tCRK
peptide is exposed at the C terminus at the time of systemic adminis-
tration and does not require proteolytic cleavage before activation of
the CendR pathway. Our in vitro studies confirmed the binding ofanti-histidine antibody (anti-his; green) on both paw and dorsal skin of col7a1/ mice
Representative double staining of anti-histidine tag (red) and anti-NRP-1 (green) and
treated, and untreated RDEB skin are presented. Scale bar, 25 mm.tCRK to NRP-1 and cell penetration of tCRK in an NRP-1-dependent
manner. In the in vitro binding analysis, we used a prototypic peptide
with an exposed CendR sequence, i.e., RPARPAR, as a positive con-
trol. It is the strongest CendR peptide characterized to date.6 When
injected into the circulation through the tail vein, the RPARPAR pep-
tide binds to NRP-1 in the first vascular bed it meets, i.e., lung, and
does not circulate to the systemic side of the circulation.6 As tCRK
is a substantially weaker NRP-1 binding peptide than RPARPAR,
tCRKmay be able to circumvent NRP-1 in the majority of the tissues.
Variable expression levels of NRP-1 in different endothelial popula-
tions and/or ideal blood flow conditions may have rendered NRP-1
available for the tCRK binding preferably in skin.
To validate the utility of tCRK as a delivery cargo for skin-targeted ther-
apies, we conjugated tCRK toDCN. In addition to binding and neutral-
izing all isoforms of TGF-b,23 DCN also competes with TGF-b receptor
3 (TGFBR3) on TGF-b binding (by having the same binding site).34,35
As TGFBR3 is an important co-receptor for TGF-b and the binding to
it enhances TGF-b signaling, the direct neutralization of TGF-b and
the inhibition of TGF-b-TGFBR3 binding by soluble DCN could be
one of the mechanisms by which DCN-tCRK exerts its biological ef-
fects. Moreover, DCN binds and neutralizes CTGF/CCN2, which is a
downstream mediator of TGF-b’s fibrotic signaling and has been pro-
posed to be a therapeutic target in the prevention of scarring.36,37 As the
binding sites for TGF-b and CCN2 reside in different parts of DCN,
DCN theoretically can simultaneously block both mediators of fibrosis.
Indeed, the role of DCN on suppressing TGF-b-driven scar formation
has been well established in numerous disease models such as renal,
lung, and hepatic fibrosis and in skin wound healing, in addition to
RDEB.18,20,24,25,32,38,39 However, despite numerous positive anti-cancer
and anti-fibrotic results in preclinical studies,22,23 DCNhas not reached
the clinic as a systemic therapy. So far, the only reported clinical appli-
cation of DCNwas in 12 patients with perforating eye injury, and a sin-
gle dose of either 200 or 400 mg of human recombinant DCN intravi-
treal injection appeared to be well tolerated with no ocular adverse
events.40
We demonstrated that systemic administration of DCN-tCRK re-
combinant protein was more effective than unmodified DCN in
improving the survival of col7a1/ mice. The exact molecular
mechanism is not known, but we assume that multiple different
mechanisms could contribute to the improved survival. DCN is an
anti-inflammatory and anti-fibrotic molecule. Consistent with our
previous finding on the activation of TGF-b signaling as early as a
week after birth,20 the expression levels of more than half of the genes
related to fibrosis formation were upregulated in the untreated RDEB
mouse skin at the 1-week time point. The improved survival of
RDEB mice by DCN-tCRK administration is likely related to the
anti-fibrotic and anti-inflammatory effects of the therapeutic protein.is presented. Nuclei were counterstained with DAPI (blue). Scale bar, 20 mm. (D)
the merged image (with DAPI counterstain; blue) of the DCN-tCRK-treated, DCN-
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Figure 5. DCN-tCRK Normalizes Fibrotic Gene
Signature in RDEB
(A) Relative gene expression in clustergram for the genes
that had a >1.5-fold increase in expression in the untreated
RDEB skin than for the WT. (B) Volcano plots on log2 fold
changes and log10 p values of gene expression in the
vehicle-, DCN-, and DCN-tCRK-treated col7a1/ mouse
skin relative to the WT.
Molecular TherapyHowever, this mechanism does not provide a plausible explanation
for the improved survival during the first week of life. In this context,
it is worth remembering the natural function of DCN. The absence of
DCN (Dcn/) leads to fragile skin due to the reduced tensile
strength.41 DCN can bind to the same fibrillar collagens expressed
in the dermis, i.e., type I, III, IV, and V collagen,42 as C7 does, and
also similar to C7, DCN is known to connect type VI collagen to
fibrillar collagens.43 Furthermore, the GAG side of DCN, in turn,
can bind to multiple ligands, among them integrins, and tCRK pep-
tide affords binding to NRP-1 in DCN-tCRK. Since DCN-tCRK has
the versatile ability to bind and connect ECM components, especially
different collagens, it could also maintain the mechanical integrity of
the skin, which it is heavily compromised in RDEB and thus improve
the survival.
Not only were the genes directly involved in TGF-b signaling normal-
ized in the DCN-tCRK-treated (but not in the DCN-treated) RDEB
skin, the genes related to other signaling pathways, such as b-catenin
and EGFR, were also normalized by DCN-tCRK administration.
Both Wnt/b-catenin and EGFR signaling have been demonstrated to
contribute to fibrogenesis in multiple fibrotic diseases through their in-
dependent, profibrotic mechanisms or via cross-talking with the TGF-
b signaling.37,38,44,45 For example, EGFR activation is required for1840 Molecular Therapy Vol. 28 No 8 August 2020profibrotic functions of TGF-b44 and CCN2-
mediated fibroblast proliferation and myofibro-
blast transdifferentiation.46,47 DCN can bind and
downregulate EGFR and HGF receptor Met (to
suppress expression of b-catenin).48,49 The
normalized expression of these genes in the
col7a1/ mouse skin after administration of
DCN-tCRK suggests multiple therapeutic func-
tions of DCN-tCRK in RDEB. The upregulation
of pro-inflammatory genes in DCN-treated
RDEB skin, in turn, may indicate a therapeutic ef-
fect that was not sustained by the administration of
native DCN.
When we analyzed skin homing of DCN-tCRK
and DCN using ELISA analysis, the amount of
DCN in the skin lysate was not statistically
different from that of DCN-tCRK at the 1-week
time point. DCN core protein has been reported
to home to angiogenesis50,51 and has been used
as a delivery vehicle for other therapeutics.52,53Most recently, a collagen-binding peptide derived from DCN
sequence was a potent delivery vehicle for therapeutics to inflamma-
tory diseases.54 It is likely that DCN also accumulated in the skin due
to highly activated vasculature, a result of hemorrhagic erosions and
active angiogenesis in the RDEB skin.55 Furthermore, the recombi-
nant DCN has a naturally occurring GAG side chain that, in turn,
can bind to a2b1-integrins on angiogenic endothelial cells.56 Impor-
tantly, C7 is a natural ligand of a2b1 integrin.55 In the absence of C7
in the RDEB skin, a2b1 integrin could be readily available for DCN
GAG chain binding and could further enhance the homing of DCN
in RDEB skin. However, despite the detection of DCN in RDEB
skin lysates, the different accumulation of DCN and DCN-tCRK in
the skin suggests distinct tissue penetration mechanisms of these
two proteins in the skin. This most probably contributes to their
different therapeutic efficacies and highlights the importance of add-
ing cell-penetrating protein domain even for the molecules such as
DCN that have intrinsic ability to home to the target organ.53 Further-
more, tissue penetration and accumulation in the skin offered by
NRP-1 could have exposed some of the DCN-tCRK ultimately unde-
tectable in DCN ELISA. Namely, cleaved DCN is found in many skin
disorders, and many proteases are known to cleave DCN.57,58 Among
these is granzyme B, which is highly active in human epidermolysis
bullosa.59
(legend on next page
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Molecular TherapyIn summary,wedemonstrate that exposure of a crypticCendR sequence
renders novel features in a wound-targeting peptide to home to normal
skin in addition to the wounded skin and also provides dermal tissue
penetration. This suggests the potential for this peptide (tCRK) to serve
as a vehicle for delivering therapeutic molecules in the treatment of sys-
temic dermal diseases. As a proof-ofprinciple study, we demonstrated
skin-selective targeting of DCN-tCRK and anti-fibrotic effect of this
therapeutic fusion protein in a murine model of RDEB.MATERIALS AND METHODS
Mice
BALB/cJRj mice (Janvier Labs, Le-Genest-Saint-Isle, France) were
used in phage screening, nanoparticle (IONW) homing, and pharma-
cokinetics. The mice were fed with standard laboratory pellets and
water ad libitum.
The col7a1/ RDEB mice were used to study the skin-homing and
therapeutic function of DCN-tCRK. The col7a1/ RDEB mice
were generated by breeding C57BL6/J col7a1+/ mice with the geno-
type determined by polymerase chain reaction (PCR).60 C57BL6/J
col7a1+/mice, kindly provided by Dr. Jouni Uitto at Thomas Jeffer-
son University, were developed by targeted ablation of the col7a1 gene
through out-of-frame deletion.60Wound Healing Models
Eight-week-old male mice (BALB/cJRj), weighing 23–25 g, were used
in pharmacokinetics and wound and skin-homing studies. Mice were
anesthetized with 4% isoflurane and 0.2 L/min of 100% oxygen mixed
with 0.4 L/min air, and the anesthesia was maintained at 2% isoflur-
ane at 0.2 L/min of 100% oxygen mixed with 0.4 L/min air. For the
generation of skin wounds, skin was shaved, cleaned, and disinfected.
Homing studies were conducted on mice that had circular, 6-mm-
diameter, full-thickness excision wounds (including panniculus car-
nosus muscle) in the dorsal skin.25 The wounds were first marked
by a biopsy punch and then cut with scissors. All skin wounds were
left uncovered without a dressing. For the excision wound splinting
model, donut-shaped 12-mm silicone splints (Grace Bio-Labs,
Bend, OR, USA) were placed around the wounds and affixed with su-
tures in order to prevent wound contraction.61,62 The splint excision
wounds and the animal welfare were checked every day, and the sil-
icone splints were re-sutured and/or analgesic was administered when
needed. The nanoparticle (IONW) synthesis, targeting, and detection
are described in Supplemental Materials and Methods.Figure 6. DCN-tCRK Administration Suppressed the Development of Fibrosis
(A) Representative immunohistochemical staining of CTGF in WT and col7a1/ mice a
(upper panel) and 25 mm (lower panel). (B) Picrosirius red staining of the paw skin from
treatment. Picrosirius red images were acquired using polarized light. Scale bar, 25 mm.
objective. Eight or more fields were acquired per section and at least four sections we
representative images of collagen type I (COLI) expression in RDEB and WT skin at 2 we
green) and blood vessels (CD31, red) in WT and col7a1/mice at 2 weeks of age with a
mm. (E) Quantification of mean immunostaining intensity for COLI and aSMA expression
1842 Molecular Therapy Vol. 28 No 8 August 2020In Vivo Phage Screening
Phage-homing studies were performed as previously described.63
Briefly, 8- to 10-week-old mice were injected with a phage clone
(1.0  109 T7 phage particles [Novagen, Madison, WI, USA] in
100 mL of M9LB medium) through the tail vein and perfused
12 min later through the heart with 1% BSA in Dulbecco’s modified
Eagle’s medium (DMEM, total perfusion volume 75 mL) to remove
unbound intravascular phage. Tissue samples were collected and dis-
rupted by a Precellys 24 homogenizer (Bertin Technologies, Mon-
tigny-le-Bretoneux, France) using CKMix tubes for wound and skin
samples and CK14 tubes for other samples. The cell and tissue
suspension was washed in a large volume of 1% BSA-DMEM and
centrifuged. For the rescue of the phage particles from tissue samples,
cell pellets were lysed with 1% Nonidet P-40 (NP-40) on ice for 5 min
and overnight BL21 (415-1b) cultures were added to the lysed cells.
The phage particles were rescued by shaking at 37C for 5 min, after
which the samples were titrated using agar plates as previously
described.63
Recombinant Protein Production
The constructs in the pEFIRES-P expression vector were transfected
via lipofection (FuGene 6, Promega, Madison, WI, USA) into
HEK293F cells. Positive clones were selected in the culture medium
composed of high-glucose DMEM (4.5 g/L) + 2 mM L-alanyl-L-gluta-
mine, 100 IU/mL penicillin (all from Sigma-Aldrich, St. Louis, MO,
USA), and 10% FBS (Gibco, Grand Island, NY, USA), in the presence
of 5–160 mg/mL puromycin (HyClone, Thermo Fisher Scientific). Es-
tablished cell lines were maintained in the culture containing 10 mg/
mL puromycin.
The validated cells were then resuspended in serum-free OptiCHO
medium (Gibco) supplemented with 2 mM L-alanyl-L-glutamine
(Sigma) and cultured in square-shaped glass bottles mounted on a
rotating shaker at 37C in a 5% CO2 atmosphere. After the cells
reached a density of 1–2  106 cells/mL, they were cultured further
for 4 days at 33C for recombinant protein expression and secretion
to the culture media. The protein was purified from the culture media
via the two-step HisTrap purification protocol on the ÄKTA start
chromatography system (GE Healthcare, Munich, Germany). A
detailed description of the purification and biophysical analysis is
in Supplemental Materials and Methods.
Administration of DCN-tCRK and DCN in col7a1–/– Mice
The pregnant col7a1+/ mice were housed individually and moni-
tored daily before delivery. As intravenous injection in neonatalin col7a1–/– Mice
t 1 and 2 weeks of age with and without DCN-tCRK treatment. Scale bars, 50 mm
the WT and col7a1/ mice at 1 and 2 weeks of age with and without DCN-tCRK
(C) Quantification of the picrosirius red mean intensity per field acquired with a 20
re analyzed per biopsy. Error bars represent SEM. *p < 0.05, **p < 0.01. (D) Left:
eks. Right: double immunofluorescence staining of a-smooth muscle actin (aSMA,
nd without DCN-tCRK treatment. Nuclei were counterstained by DAPI. Scale bar, 25
on skin sections (n = 3 in each treatment group). *p% 0.05, **p < 0.01, ***p < 0.001.
www.moleculartherapy.orgmice is technically challenging and often yields inconsistent results,
we chose to inject within 24 h of birth the first dose of DCN-tCRK
and DCN (5 mg in 15 mL of PBS, corresponding to ~5 mg/kg) into
the liver of the col7a1/ mice, since liver is a primary site of hema-
topoiesis in fetal and neonatal mice, and the human cells have been
shown to rapidly enter the circulation after intrahepatic injection.30,31
This first dose was followed by repeated i.p. administration of the pro-
tein every other day until the mice reached 14 days of age (maximum
of seven doses) and the dose was increased to 10 mg when the mice
became a week old. The mice were monitored every day. All of the
experimental col7a1/ mice were genotyped at the time of sample
collection.
RT2 Profiler PCR Wound Healing Pathway Analysis
The expressions of genes involved in the mouse wound healing
pathway were studied using RT2 Profiler PCR array (QIAGEN, Hil-
den, Germany). The RT2 Profiler array contains primers for 84
wound-healing genes and 5 housekeeping genes with genomic
DNA, reverse-transcriptional, and PCR positive controls in 96-well
plates. Total RNA was isolated from whole front paw of WT,
RDEB, and DCN- or DCN-tCRK-injected col7a1/ mice (three
mice in each group) at day 7. Quality and concentration of RNA
were determined with a NanoDrop 200C (Thermo Scientific, Wal-
tham, MA, USA). RNA was treated with genomic DNA elimination
mix (QIAGEN). 500 ng of total RNA of each sample was applied
for reverse transcription using an RT2 First Strand kit (QIAGEN).
cDNA synthesis reaction was combined with 2 RT2 SYBR Green
master mix, and 25 mL of this cocktail was dispensed in each well
of a 96-well plate. qPCR was run on QuantStudio 5 real-time PCR in-
strument (Applied Biosystems, Foster City, CA, USA). CT values
were exported to an Excel file. The resulting raw data were analyzed
using the PCR Array Data Analysis template in the GeneGlobe Data
Analysis Center (https://geneglobe.qiagen.com). A gene expression
was calculated using the DDCT method. A fold-change gene expres-
sion threshold of 1.5 and a p value threshold of 0.05 were used to
analyzed data between WT pups and untreated/treated pups.
Histological and Immunohistochemical Staining and hDCN
Quantitation in col7a1–/– Mice
Dorsal skin and paws (front and rear) were excised from selected
mice, embedded in Tissue-Tec OCT compound (Sakura Finetek, Tor-
rance, CA, USA), and stored at 80C. 6-mm serial sections were cut
for each specimen. Picrosirius red staining and anti-CTGF/CCN2
(connective tissue growth factor) (#ab6992, Abcam, Cambridge,
UK) immunohistochemical staining were performed at the Core His-
tology Lab of New YorkMedical College. For immunochemical stain-
ing of his tag, the sections were fixed in 4% paraformaldehyde and
blocked with M.O.M. blocking reagent (Vector Laboratories, Burlin-
game, CA, USA) (for antibodies raised in mouse) or 10% horse serum
(Gibco, Grand Island, NY, USA) with 0.1% Triton X-100 (Sigma, St.
Louis, MO, USA). The slides were then incubated with respective pri-
mary antibodies, including anti-Col1A (#R1038, Acris, Rockville,
MD, USA), anti-aSMA (#14968, Cell Signaling Technology, Danvers,
MA, USA), anti-6-His tag (#R930-25, Thermo Fisher Scientific,Carlsbad, CA, USA), and anti-NRP-1 (#AF566-SP, R&D Systems,
Minneapolis, MN, USA), followed by corresponding Alexa Fluor
488 secondary antibodies (Invitrogen, Carlsbad, CA, USA). The slides
were then mounted in Vectashield mounting medium containing
DAPI (Vector Laboratories, Burlingame, CA, USA). Images were ac-
quired using Nikon 90i Eclipse microscope (Nikon Instruments, NY,
USA) using the same settings between the different groups in each set
of experiments. Intensity of the immunostaining per field was
measured using NIS-Elements AR software, following the user’s
guide. The RGB images were used for the quantitation of picrosirius
red staining, and the threshold was defined by choosing reference
points within the image.
The homing of DCN-tCRK and DCN to skin in col7a1/ mice was
determined using a hDCNDuoSet ELISA kit (#DY143, R&D Systems,
Minneapolis, MN, USA), according to the manufacturer’s recom-
mendations. Tissue biopsies were snap-frozen in liquid nitrogen,
ground with a precooled pestle, and homogenized with lysis buffer
(1% Tween 20, protease inhibitor cocktail, DNase, and RNase in
PBS). After centrifugation at 12,000 g for 10 min at 4C, the super-
natant was collected and quantitated for total protein concentration
with the Bio-Rad DC protein assay (Bio-Rad, Hercules, CA, USA).
Sera from col7a1/ mice with and without DCN-tCRK or DCN
administration were diluted 1:20 in sample diluent before applying
to the assay.
Statistical Analysis
Kaplan-Meier analysis was applied to determine the median lifespan,
and a log rank (Mantel-Cox) test was used to compare survival
between different experimental groups (GraphPad Prism 6). A Krus-
kal-Wallis test and Bonferroni post hoc correction for pairwise com-
parisons were used to study phage homing, and a Student’s unpaired t
test was used for DCN-tCRK binding to NRP-1. p values less than
0.05 were considered significant. SPSS version 24 was used for these
tests.
Study Approval
All animal experiments with the BALB/cJRj mice were performed in
accordance with protocols approved by the National Animal Ethics
Committee of Finland, and all animal studies with the col7a1/
RDEB were conducted using protocols approved by New York Med-
ical College Institutional Animal Care and Use Committee (IACUC).
Additional Methods
Generation of phage clones, synthesis of nanoparticles (IONWs),
in vitro binding analyses, nanoparticle targeting studies, cloning of
the DCN fusion proteins, recombinant protein purification and bio-
physical analyses, collagen gel contraction assay, as well as pharmaco-
kinetics were performed using standard, published methods8,28,64,65
and are described in detail in Supplemental Materials and Methods.
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